Issue navigation
Volume 11, Issue 3, May 2025
Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 230–240, https://doi.org/10.1093/ehjcvp/pvae087
Editorial
Bleeding and thrombosis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 211–212, https://doi.org/10.1093/ehjcvp/pvaf017
Invited Editorials
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 213–214, https://doi.org/10.1093/ehjcvp/pvaf008
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 215–217, https://doi.org/10.1093/ehjcvp/pvaf011
Original Articles
A pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction: the TITIAN study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 218–229, https://doi.org/10.1093/ehjcvp/pvae100
Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 241–250, https://doi.org/10.1093/ehjcvp/pvae097
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 251–263, https://doi.org/10.1093/ehjcvp/pvaf005
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 264–274, https://doi.org/10.1093/ehjcvp/pvaf015
Review
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy: A clinical consensus statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care (ACVC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy and the European Association for Haemophilia and Allied Disorders (EAHAD)
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 275–289, https://doi.org/10.1093/ehjcvp/pvaf006
Correspondence
Inotropes and mortality in patients with cardiogenic shock: more questions than answers
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 290–291, https://doi.org/10.1093/ehjcvp/pvaf010
Review
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 292–317, https://doi.org/10.1093/ehjcvp/pvaf012
Correction
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Page 318, https://doi.org/10.1093/ehjcvp/pvaf013
